US2005124583A1PendingUtilityA1
Prodrugs of phosphonate nucleotide analogues
Priority: Jul 21, 2000Filed: Jan 6, 2005Published: Jun 9, 2005
Est. expiryJul 21, 2020(expired)· nominal 20-yr term from priority
Inventors:Mark BeckerHarlan ChapmanTomas ClhlarEugene ElsenbergGong-Xin HeMichael KernanWilliam A. LeeErnest J. PrisbeJohn C. RohloffMark Sparacino
A61P 31/20A61P 35/00A61P 43/00A61P 31/18A61P 31/00A61P 31/12C12Q 1/18C07H 21/00C07H 19/10C07F 9/65616C07H 19/20A61P 1/16G01N 33/5011C12Q 1/70
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
Claims
exact text as granted — not AI-modified1 . A fumarate salt of a nucleotide analog compound according to structural formula (Ia):
that comprises at least about 60% by weight a diastereomer according to structure (Ib):
2 . The fumarate salt of claim 1 in which the nucleotide analog compound comprises at least about 80% by weight the diastereomer of structure (Ib).
3 . The fumarate salt of claim 1 in which the nucleotide analog compound comprises at least about 95% by weight the diastereomer of structure (Ib).
4 . The fumarate salt of claim 1 in which the nucleotide analog compound comprises at least about 99% by wieight the diastereomer of structure (Ib).Join the waitlist — get patent alerts
Track US2005124583A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.